← Acquirers
Has Leading Technology Group approached you? Here’s what to do.
Acquirer profileAustralia
Who is Leading Technology Group?
Leading Technology Group is a serial acquirer based in Australia.
Firm facts
Leading Technology Group
- Type
- serial acquirer
- Headquarters
- Australia
- Website
- leadingtechnology.com
- Company page
Industries
Last verified 2026-08-02
How they work
Leading Technology Group (LTG) is a Melbourne-based, family-owned investment company founded in 1991 that acquires and permanently holds service and technology businesses in the medical research, life sciences, health and software industries, favouring a buy-and-hold-forever, no-debt approach over a typical private-equity fund model.
LTG describes itself as buying businesses to hold them forever, not as a fund working toward an exit. It states no defined hold period. Deals are self-funded with no debt required, which LTG says lets it move quickly, completing acquisitions and investments in a matter of months. Owners of businesses LTG acquires typically keep an ongoing role, though LTG says this isn't required. LTG positions itself as building long-term relationships with the people who built the business. LTG does not publish a diligence checklist, a first-contact process or a stage-by-stage transaction timetable.
- Sector focus
- Service and technology businesses in medical research, life sciences, health and software, with a historical concentration on biological/software products for medical and research groups and, since 2013, a stated strategic emphasis on vascular- and brain-ageing research and ventures aimed at extending peak health-span without permanently altering human physiology.
- Ownership
- Buy-and-hold-forever acquirer -- LTG states it does not buy businesses to sell later and is a 'permanent home' for the businesses it acquires, explicitly contrasting this with private-equity funds that hold for a defined period before exit.
- Capital model
- Self-funded, no-debt permanent capital -- LTG states it completes acquisitions and investments 'in a matter of months with rapid decision making and no debt required.'
- Hold period
- Permanent / indefinite -- LTG states it buys businesses 'to hold them forever' and is not seeking to sell acquired businesses later.
- Founder ownership
- LTG states it maintains 'great ongoing relationships with the owners of acquired businesses with all enjoying ongoing roles in the businesses (though not required)'; LTG itself is also family owned and run, with the owners playing an active leadership role.
Their portfolio
Company
Sector
What they do
- SectorCardiovascular clinical information management softwareWhat they doProvides a cardiovascular information management system used by more than 27 hospital cardiac departments across Australia, the UK and New Zealand, combining administration, medical records and analytics to improve department efficiency and patient outcomes.
- SectorClinical trial participant recruitment and clinical-trial-management software (CTMS)What they doAn Australian clinical trial participant recruitment company that also provides a Clinical Trial Management Software (CTMS) and eSource platform used to register and match participants to trials across all disease areas and regions.
- SectorBioanalytical laboratory services (immunology / biomarker testing for CROs)What they doAn Australian bioanalytical laboratory providing immunology, biomarker-detection and other specialist testing services to contract research organisations for clinical and pre-clinical trials.
- SectorClinical trial site / contract research organisation (CRO)What they doA Melbourne-based clinical medicine research centre delivering Phase I/Ib, II, III and IV clinical trials, including health-economic and pharmacoeconomic studies, for pharmaceutical and biotech sponsors.
- SectorScientific instrumentation and reagent distribution (life sciences)What they doDistributes high-technology laboratory instrumentation systems and reagents -- including cell-imaging, multiplexing and plate-reader platforms from suppliers such as Agilent and Mabtech -- to biotechnology and life-science researchers across Australia and New Zealand.
- SectorBiotechnology / precision DNA sequencing and ageing-related drug discoveryWhat they doA Melbourne biotechnology company developing high-accuracy DNA sequencing methods to detect low-frequency clonal mutations, building drug-discovery models and therapies that target the molecular drivers of cancer and age-related disease.
- SectorClinical trial participant recruitment (CRO services)What they doA Melbourne-based clinical research organisation and Phase I trial centre that recruits both complex-disease patients and healthy volunteers for pharmaceutical and biotech sponsors, covering conditions such as arthritis, cardiovascular disease, dermatitis and diabetes.
Exited holdings
Confirmed former portfolio companies, shown separately from current holdings.
Company
Sector
What they do
- LeadtecSectorCloud-based EDI and supply-chain software (retail industry)What they doFormerly Australia's leading provider of cloud-based EDI and supply-chain software solutions for the Australian and New Zealand retail industry (Leadtec Systems Australia), connecting thousands of trading partners before its October 2014 sale to SPS Commerce, Inc. (exited)
Sources
- leadingtechnology.com · portfolio page
- au.linkedin.com · research
- leadingtechnology.com · research
- leadingtechnology.com · research
- leadingtechnology.com · research
- leadingtechnology.com · website
The truth, first.Data as at 2026-08-02